Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRA-216
- Development stage
- Phase 2
- Lead developer
- Prana Therapies
- Administration
- Intravenous, Subcutaneous
01
Overview
PRA-216 is an investigational biologic agent developed by Prana Therapies for the treatment of asthma. It is currently being evaluated in a Phase 1/2a clinical trial (NCT07245368) assessing safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy in healthy volunteers and participants with mild-to-moderate asthma. The trial includes single ascending dose (SAD) and multiple ascending dose (MAD) cohorts administered via intravenous (IV) or subcutaneous (SC) routes, with Phase 2a focusing on efficacy endpoints such as fractional exhaled nitric oxide (FeNO), a biomarker of airway inflammation.[1][3][9]
Beyond the preview
Go deeper on PRA-216.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRA-216.